Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BLM
REST API REST API
Homo sapiens
BLM is differentially expressed in 265 experiments: 106 organism parts: bone marrow, prostate, ... (104 more);, 161 disease states: normal, glioblastoma, ... (159 more);, 90 cell types 265 cell lines 40 compound treatments and 69 other conditions.
Synonyms BS, RECQL3, RECQ2
Orthologs Blm (Mus musculus)   BLM (Bos taurus)   blm (Danio rerio)   SGS1 (Saccharomyces cerevisiae)   D3ZSJ5_RAT (Rattus norvegicus)   BLM (Gallus gallus)   mus309 (Drosophila melanogaster)   blm (Xenopus laevis)   BLM (Canis familiaris)   (Compare orthologs)
Gene Ontology Term chromosome, telomeric region, telomere maintenance, DNA binding, double-strand break repair via homologous recombination, protein binding, DNA repair, cytoplasm, cellular metabolic process, intracellular, regulation of cyclin-dependent protein kinase activity, ATPase activity, male germ cell nucleus, ATP-dependent helicase activity, replication fork, nucleic acid binding, nuclear matrix, single-stranded DNA binding, ATP-dependent 3'-5' DNA helicase activity, negative regulation of mitotic recombination, replication fork protection, four-way junction helicase activity, protein oligomerization, ATP binding, nucleus, ATP-dependent DNA helicase activity, DNA recombination, nucleotide binding, DNA strand annealing activity, hydrolase activity, response to DNA damage stimulus, response to X-ray, catalytic activity, G2/M transition DNA damage checkpoint, positive regulation of transcription, DNA-dependent, chromosome organization, DNA replication, nucleolus, hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides, helicase activity, positive regulation of alpha-beta T cell proliferation, regulation of binding, G-quadruplex DNA binding, negative regulation of cell division, replication fork processing, ATP catabolic process, DNA strand renaturation, alpha-beta T cell differentiation, bubble DNA binding, lateral element, pronucleus, negative regulation of DNA recombination, PML body, p53 binding, G2 phase of mitotic cell cycle
InterPro Term Helicase/RNaseD_C, DNA/RNA_helicase_DEAD/DEAH_N, BDHCT, RQC_domain, Helicase_C, DNA_helicase_ATP-dep_RecQ, DEAD-like_helicase
UniProt Accession P54132, F5H7R6, F5H3V6
Gene-Disease Assocation BLOOM SYNDROME; BLM
Search EB-eye ENSG00000197299
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (32 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MCF-7
2
E-GEOD-19639, E-GEOD-20081
Jurkat
1
2
E-MTAB-62, E-GEOD-1880, E-MEXP-2197
SKMEL1
1
E-MTAB-37
293t-tva
1
E-MTAB-62
C7H2-R9C10
1
E-GEOD-22152
259 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, E-GEOD-20677, ... (44 experiments)

Factor Value U/D Experiments
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
fibroblast
1
2
E-GEOD-3920, E-MEXP-466, E-GEOD-3204
CD19+ B cell
1
E-MEXP-1600
germ cell
1
E-MTAB-25
84 more value(s).


Disease state

studied in E-GEOD-1577, E-TABM-15, E-GEOD-16363, E-MTAB-62, E-GEOD-8607, ... (51 experiments)

Factor Value U/D Experiments
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-GEOD-6014, E-MTAB-62
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
control
2
E-GEOD-21912, E-GEOD-16363
lung adenocarcinoma
2
E-MTAB-37, E-GEOD-2514
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
155 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-697, E-TABM-782, E-GEOD-3720, ... (26 experiments)

Factor Value U/D Experiments
none
5
8
E-TABM-782, E-GEOD-5824, E-MEXP-1601, E-GEOD-412, E-MEXP-1958, ... (13 experiments)
Cxcl12
1
E-GEOD-7307
U0126
1
E-GEOD-697
nickel(II) chloride hexahydrate
1
E-GEOD-6907
unknown
1
E-GEOD-7307
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2034, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-958, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (11 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-TABM-601, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-22541, E-GEOD-16363

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-2748

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.297 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM